Appointment of life science industry veteran adds extensive field sales experience to the company’s executive team.
July 17, 2012
SAN FRANCISCO, California, July 17, 2012 -- Real Time Genomics, Inc., a leading developer of biocompute technology, today announced the appointment of Pamela Jeffers Morley, Ph.D., as Vice President of Worldwide Commercial Operations. As an accomplished life science industry sales executive, Morley adds extensive field operations experience to the management team as it prepares to ramp up itʼs commercial activities.
“I am exceedingly pleased to have Pam Morley, a longtime colleague, join the company,” said Steve Lombardi, CEO of Real Time Genomics. “She has been at the forefront of the commercialization of many of the innovations in molecular biology. Her breadth of field expertise and experience will be instrumental in driving the companyʼs commercial success.”
Morley has 25+ years of experience in sales, management, and customer service and support for genomic and proteomic systems. Throughout her career she has successfully introduced highly innovative technologies to the market, and built distribution channels for their long-term success. Most recently, from 2006 to 2011, she was VP, North America Sales, Service and Support and Channel Manager for South America; and VP, Global Accounts at Fluidigm Corporation. Prior to that, in a two-decade long period at Applied Biosystems, Morley developed an increasingly broad view of field operations. From 2002 to 2006, she was a Director of Service for the molecular biology, and the proteomics and mass spectrometry product lines. Before 2002, she held numerous regional sales and district manager positions covering core technologies, such as automated fluorescent DNA sequencing, real-time quantitative PCR, and DNA synthesis. She earned her Ph.D. in Physical Chemistry and completed a post doctorate fellowship in Fluorescence at the University of Virginia.
“Introducing innovative life science and biotechnology products has always been a passion of mine, and being the bridge between the technology and our customers is most rewarding,” said Pam Morley. “I am pleased to have the opportunity at Real Time Genomics to build advanced application-based partnerships for the development and execution of our commercialization strategy, to develop and implement field-based distribution channels and operations for sales and support, and establish commercial processes for its highly scalable core technology for genomic analysis.”
Real Time Genomics (www.realtimegenomics.com) has a passion for genomics. The company offers software solutions for the extraction of unique value from genomes. Itʼs core competency lies in applying its own patented pattern search technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd of Hamilton NZ.